Bharat Immunologicals & Biologicals Corp. Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net salesincome from operations (net off excise duty) of INR 240.425 million compared to INR 390.518 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 23.563 million compared to INR 0.844 million a year ago. Profit from ordinary activates before tax was INR 15.6714 million compared to loss of INR 10.956 million a year ago. Net profit was INR 14.323 million or INR 0.33 per basic and diluted share before and after extraordinary items (not annualized) compared to loss of INR 6.862 million or INR 0.16 per basic and diluted share before and after extraordinary items (not annualized) a year ago. For the nine months period, the company reported net salesincome from operations (net off excise duty) of INR 628.439 million compared to INR 690.422 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 40.140 million compared to loss from operations before other income, finance costs and exceptional items of INR 84.969 million a year ago. Profit from ordinary activates before tax was INR 35.071 million compared to loss from ordinary activates before tax of INR 90.071 million a year ago. Net profit was INR 25.972 million or INR 0.60 per basic and diluted share before and after extraordinary items (not annualized) compared to net loss of INR 63.101 million or INR 1.46 per basic and diluted share before and after extraordinary items (not annualized) a year ago.